Poor
Mostly Not Aligned
Patient Risk:
Medium
Summary
Substantial portions of the response are not supported by the supplied FDA label content (notably pricing and brand-specific patient assistance/coverage assertions). While some clinical/safety claims align with label text provided (e.g., dosing, hypocalcemia, ONJ, and reduction of bone resorption), multiple other claims are unsupported or only partially supported based on the provided label excerpts.
Category Scores
Accurate Statements
Prolia is a monoclonal antibody that works by inhibiting osteoclast activity, thereby reducing bone breakdown.
Partially supported by label mechanism describing binding to RANKL and inhibition of osteoclast formation/function/survival leading to decreased bone resorption.
Prolia reduces bone resorption.
Supported by supplied label mechanism content (12 Clinical Pharmacology / 12.1).
More serious, though less common, side effects of Prolia can include low calcium levels (hypocalcemia).
Supported by Warnings and Precautions (5.1) severe hypocalcemia/mineral metabolism changes.
Prolia can cause a rare but serious side effect called osteonecrosis of the jaw (ONJ).
Supported by Warnings and Precautions (5.4) Osteonecrosis of the Jaw.
The standard dosage for Prolia is a 60 mg injection administered subcutaneously once every six months.
Supported by Dosage and Administration (2.3) recommended dosage.
Unsupported Statements
The average retail price for Prolia (denosumab) injections in the United States can range between $1,000 and $2,500 for a 60 mg prefilled syringe.
No retail pricing statements are present in the supplied FDA label excerpts; outside label scope.
Actual out-of-pocket expense for Prolia may be substantially lower due to patient assistance programs and insurance coverage.
The supplied label excerpts do not describe patient assistance, expected out-of-pocket costs, or savings.
Amgen offers the Amgenfirst™ Patient Support Program, which can provide co-pay assistance for eligible commercially insured patients.
Brand-specific patient support program details are not contained in the supplied label excerpts.
The Amgenfirst™ Patient Support Program could reduce out-of-pocket costs for Prolia to as little as $0 per dose.
No such program outcomes or $0-per-dose statements exist in the supplied label excerpts.
Uninsured patients may qualify for the Amgen Safety Net Foundation.
No foundation eligibility statements are present in the supplied label excerpts.
The Amgen Safety Net Foundation provides Prolia at no cost to eligible individuals.
No no-cost foundation statements are present in the supplied label excerpts.
Insurance coverage for Prolia varies widely depending on the specific plan.
No insurance coverage statements are present in the supplied label excerpts.
Most insurance providers offer some level of coverage for Prolia.
No insurance coverage generalizations are present in the supplied label excerpts.
Even with coverage, deductibles, co-pays, and co-insurance can still result in significant patient expenses for Prolia.
No statements about deductibles/copays/coinsurance or expected patient expenses are present in the supplied label excerpts.
Prolia is primarily prescribed to treat osteoporosis in postmenopausal women who are at increased risk of fracture.
The provided label excerpts include no indication statements from the Indications and Usage section; this is not supported by the supplied label content.
Prolia is used to treat bone loss in men and women taking certain cancer drugs that cause bone loss.
The provided label excerpts include no indication statements from the Indications and Usage section; this is not supported by the supplied label content.
Prolia is used to treat giant cell tumor of bone in certain adults and adolescents.
The provided label excerpts include no indication statements from the Indications and Usage section; this is not supported by the supplied label content.
Common side effects of Prolia include pain in the extremities, urinary tract infections, and nausea.
The supplied label excerpts do not list or support these as 'common side effects' (no adverse reactions list content provided).
Contradictions
Important Omissions
Critical contraindications and associated label details (e.g., hypocalcemia, pregnancy/fetal harm, hypersensitivity) were not mentioned in the response.
Importance:
Moderate
Key administration instruction that Prolia should be administered by a healthcare provider was not explicitly stated.
Importance:
Moderate
Label-required calcium and vitamin D supplementation and post-dose calcium/mineral monitoring guidance (10–14 days in certain patients) were not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Response includes multiple unsupported non-label claims (pricing/assistance/coverage). Although it mentions some important safety issues (hypocalcemia; ONJ) and correct dosing, it omits several label-critical safety instructions (calcium/vitamin D supplementation, monitoring, and contraindications/pregnancy/hypersensitivity), which could reduce labeling-completeness depending on context.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Multiple claims are not supported by the supplied FDA label excerpts, especially retail pricing and brand-specific patient assistance/insurance coverage statements; additionally, key labeling safety instructions and contraindications are omitted.
Suggested Improvement
Remove or qualify all non-label-supported pricing/assistance/coverage claims; ensure inclusion of label-required safety elements present in the supplied sections (calcium/vitamin D supplementation, hypocalcemia monitoring guidance, and contraindications such as hypocalcemia/pregnancy/hypersensitivity where relevant), and base indication statements on the Indications and Usage section text.